Establishment Labs (ESTA) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
9 Apr, 2026Executive summary
Q4 2025 revenue reached $64.6 million, up 45.2% year-over-year, with full-year revenue at $211.1 million, a 27.2% increase over 2024.
US Motiva revenue was $17.3 million in Q4 and $45.6 million for the full year.
Net loss from operations in Q4 was $3.9 million, down 79% from Q4 2024; adjusted EBITDA was +$5.5 million, a significant turnaround from -$13.1 million last year.
Ended 2025 with $75.6 million in cash, up $4.9 million sequentially, and no need for additional capital.
Management transition announced: Raj Denhoy to SVP, Global Strategy; Cassandra Harris appointed CFO.
Financial highlights
Q4 gross profit was $45.5 million (70.5% margin), up from $30.5 million (68.5% margin) in Q4 2024.
SG&A expenses were $44.0 million, flat year-over-year; total operating expenses for Q4 were $49.5 million.
R&D expenses for Q4 were $5.4 million.
Adjusted EBITDA improved by $18.6 million year-over-year in Q4.
Full-year net loss was $51.1 million, improved from $84.6 million in 2024.
Outlook and guidance
2026 revenue guidance is $264–$266 million, representing 25–26% growth over 2025.
2027 revenue growth is projected to be at least 25%.
US expected to exceed 30% of overall sales in 2026, up from 22% in 2025.
Gross margins projected to increase by 200–300 basis points in 2026.
Adjusted EBITDA positive every quarter in 2026; cash flow positive expected in 2026, with no further equity raises needed.
2027 expected to be cash flow positive for the full year, with further margin improvement.
Latest events from Establishment Labs
- Virtual meeting to elect directors, approve pay, and ratify auditor, with strong governance focus.ESTA
Proxy filing10 Apr 2026 - Vote on directors, executive pay, and auditor ratification at the May 2026 annual meeting.ESTA
Proxy filing10 Apr 2026 - Motiva's U.S. growth outpaced expectations, with premium pricing and innovation fueling expansion.ESTA
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Q2 revenue rose 18.7% sequentially; FDA approval for Motiva Implants expected soon.ESTA
Q2 20242 Feb 2026 - Innovation, global expansion, and regulatory progress position the company for rapid growth.ESTA
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - U.S. approval nears as global expansion and premium product launches drive margin growth.ESTA
Jefferies Global Healthcare Conference31 Jan 2026 - US market share surges with FDA-approved, innovative implants and strong financial momentum.ESTA
44th Annual J.P. Morgan Healthcare Conference30 Jan 2026 - Q3 revenue grew, losses narrowed, and U.S. Motiva launch plus new funding boosted outlook.ESTA
Q3 202415 Jan 2026 - FDA approval and U.S. launch drive growth outlook, with 2025 set as a transformative year.ESTA
UBS Global Healthcare Conference14 Jan 2026